Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.

Aging - 24 Feb 2020

Wang Qinghua, Li Meiling, Yang Meng, Yang Yichen, Song Fengju, Zhang Wei, Li Xiangchun, Chen Kexin

Abstract excerpt

Immune checkpoint blockade (ICB) therapies have revolutionized the treatment of human cancers including lung adenocarcinoma (LUAD). However, our understanding of the immune subtyping of LUAD and its association with clinical response of immune checkpoint inhibitor remains incomplete. Here we performed molecular subtyping and association analysis of LUAD from the Cancer Genome Atlas (TCGA) and validated findings...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Gene Expression Regulation, Neoplastic

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Prognosis

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 32091408
DOI: 10.18632/aging.102814
PMCID: PMC7066911

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.PMID 32091408Read ↗

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genesSemantic proximity Read ↗

Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for ImmunotherapySemantic proximity Read ↗

Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.Semantic proximity Read ↗

An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.Semantic proximity Read ↗

Unraveling the Expression Patterns of Immune Checkpoints Identifies New Subtypes and Emerging Therapeutic Indicators in Lung AdenocarcinomaSemantic proximity Read ↗

CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung AdenocarcinomaSemantic proximity Read ↗

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.Semantic proximity Read ↗

Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.Semantic proximity Read ↗

Systematic construction and validation of an immune prognostic model for lung adenocarcinomaSemantic proximity Read ↗

An Immune Gene Signature for Prediction of Overall Survival and Response to Immune Checkpoint Inhibitors Therapy in Patients with Lung AdenocarcinomaSemantic proximity Read ↗

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancerSemantic proximity Read ↗

A novel immune checkpoint-based signature predicts immunotherapy benefit in "driver gene-negative" lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.